Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Activities
Net income	$ 85,971	$ 54,488
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	17,478	11,967
Gain on sale of asset	0	1,133
Deferred income taxes	31,591	19,517
Amortization of debt origination costs	5,433	5,904
Stock-based compensation costs	7,098	4,919
Loss on extinguishment of debt	451	0
Lease termination costs	0	1,125
(Gain) loss on sale or disposal of property and equipment	(36)	321
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	2,453	2,113
Inventories	(7,114)	14,478
Prepaid expenses and other current assets	5,472	7,598
Accounts payable	(17,553)	(25,452)
Accrued liabilities	5,207	8,297
Net cash provided by operating activities	136,451	104,142
Investing Activities
Purchases of property and equipment	(2,540)	(3,700)
Proceeds from the sale of property and equipment	344	0
Proceeds from sale of business	0	18,500
Proceeds from sale of asset	0	10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	7,237	0
Net cash provided by (used in) investing activities	5,041	(802,857)
Financing Activities
Term loan borrowings	0	720,000
Term loan repayments	(50,000)	(80,000)
Borrowings under revolving credit agreement	15,000	124,600
Repayments under revolving credit agreement	(81,100)	(58,500)
Payments of debt origination costs	(4,211)	(16,072)
Proceeds from exercise of stock options	6,600	3,654
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,850	1,030
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,688)
Net cash (used in) provided by financing activities	(113,504)	693,081
Effects of exchange rate changes on cash and cash equivalents	(333)	(746)
Increase (decrease) in cash and cash equivalents	27,655	(6,380)
Cash and cash equivalents - beginning of period	21,318	28,331
Cash and cash equivalents - end of period	48,973	21,951
Interest paid	58,867	49,435
Income taxes paid	9,014	7,135
Insight Pharmaceuticals
Investing Activities
Acquisition of the Hydralyte brand	0	(749,666)
Hydralyte
Investing Activities
Acquisition of the Hydralyte brand	$ 0	$ (77,991)